Stevanato Group (NYSE:STVN) Hits New 1-Year Low at $21.25

Shares of Stevanato Group S.p.A. (NYSE:STVN - Get Free Report) hit a new 52-week low during trading on Thursday . The company traded as low as €21.25 ($22.85) and last traded at €22.48 ($24.17), with a volume of 381924 shares. The stock had previously closed at €26.91 ($28.94).

Wall Street Analyst Weigh In

A number of brokerages have weighed in on STVN. Morgan Stanley restated an "equal weight" rating and set a $30.00 price objective on shares of Stevanato Group in a research note on Monday, April 22nd. Stephens reissued an "overweight" rating and set a $38.00 price target on shares of Stevanato Group in a research report on Monday, March 25th. Finally, BNP Paribas started coverage on shares of Stevanato Group in a report on Monday, April 22nd. They set an "outperform" rating for the company. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of €34.29 ($36.87).

Stevanato Group Stock Down 21.6 %

The stock's fifty day simple moving average is €29.36 and its two-hundred day simple moving average is €29.04. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.50 and a quick ratio of 1.06. The company has a market capitalization of $6.24 billion, a price-to-earnings ratio of 36.05, a PEG ratio of 2.92 and a beta of 0.76.

Stevanato Group (NYSE:STVN - Get Free Report) last announced its quarterly earnings data on Thursday, March 7th. The company reported €0.18 ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of €0.19 ($0.20) by (€0.01) (($0.01)). Stevanato Group had a net margin of 13.43% and a return on equity of 14.31%. The business had revenue of €320.60 million for the quarter, compared to the consensus estimate of €326.85 million. During the same period in the prior year, the company earned $0.19 EPS. Stevanato Group's quarterly revenue was up 9.8% on a year-over-year basis. On average, sell-side analysts predict that Stevanato Group S.p.A. will post 0.67 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STVN. Raymond James & Associates boosted its holdings in shares of Stevanato Group by 0.9% during the third quarter. Raymond James & Associates now owns 197,316 shares of the company's stock valued at $5,864,000 after acquiring an additional 1,806 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Stevanato Group during the 3rd quarter valued at about $255,000. Conestoga Capital Advisors LLC grew its position in Stevanato Group by 19.7% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 4,534,088 shares of the company's stock worth $134,753,000 after purchasing an additional 746,136 shares during the last quarter. Fifth Third Bancorp increased its stake in shares of Stevanato Group by 70.1% in the third quarter. Fifth Third Bancorp now owns 2,473 shares of the company's stock valued at $73,000 after purchasing an additional 1,019 shares during the period. Finally, Sivik Global Healthcare LLC raised its holdings in shares of Stevanato Group by 8.7% during the third quarter. Sivik Global Healthcare LLC now owns 76,072 shares of the company's stock valued at $2,261,000 after buying an additional 6,072 shares during the last quarter.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.